Top Markets
Coin of the day
Moleculin Biotech, Inc. Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX
Rangering i aksjer #35911
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to... Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Aksjekurs
$0.6155
Sist synkronisert: 2026-08-14
Markedsverdi
$3.28M
Endring (1 dag)
7.74%
Endring (1 år)
-96.39%
Land
US
Handel Moleculin Biotech, Inc. (MBRX)

Kategori

Historikk for aksjesplitt for Moleculin Biotech, Inc. (MBRX)
Aksjen Moleculin Biotech, Inc. (symbol: MBRX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 16, 2026.
Én MBRX-aksje kjøpt før Aug 16, 2026 tilsvarer i dag 0 MBRX-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE